CoChat

Prostate-Specific Membrane Antigen-Targeted Therapy in Prostate Cancer: History, Combination Therapies, Trials, and Future Perspective

Open access
Mattana, Francesco, Muraglia, Lorenzo, Barone, Antonio, Colandrea, Marzia, Saker Diffalah, Yasmina, Provera, Silvia, Cascio, Alfio Severino, Omodeo Salè, Emanuela, Ceci, Francesco · 2024 · Cancers

The DOI matches its Crossref record; 60 of the 61 references it cites were found in a registry or an index.

Abstract

In the last decades, the development of PET/CT radiopharmaceuticals, targeting the Prostate-Specific Membrane Antigen (PSMA), changed the management of prostate cancer (PCa) patients thanks to its higher diagnostic accuracy in comparison with conventional imaging both in staging and in recurrence. Alongside molecular imaging, PSMA was studied as a therapeutic agent targeted with various isotopes. In 2021, results from the VISION trial led to the Food and Drug Administration (FDA) approval of [177Lu]Lu-PSMA-617 as a novel therapy for metastatic castration-resistant prostate cancer (mCRPC) and set the basis for a radical change in the future perspectives of PCa treatment and the history of Nuclear Medicine. Despite these promising results, primary resistance in patients treated with single-agent [177Lu]Lu-PSMA-617 remains a real issue. Emerging trials are investigating the use of [177Lu]Lu-PSMA-617 in combination with other PCa therapies in order to cover the multiple oncologic resistance pathways and to overcome tumor heterogeneity. In this review, our aim is to retrace the history of PSMA-targeted therapy from the first preclinical studies to its future applications in PCa.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers16091643

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 60 references

Research works printed but not linked: 2

  1. (2023, January 9). EAU Guidelines. Proceedings of the Presented at the EAU Annual Congress, Milan, Italy.
  2. Sathekge, 2023, AcTION: A phase 1 study of [225Ac]Ac-PSMA-617 in men with PSMA-positive prostate cancer with or without prior [177Lu]Lu-PSMA-617 radioligand therapy, In: Annual Congress of the European Association of Nuclear Medicine, 3–13 September 2023, Vienna, Austria, J. Nucl. Med., 50, S152

Cited by

See all 19

Metadata

Authors
Mattana, F., Muraglia, L., Barone, A., Colandrea, M., Saker Diffalah, Y., Provera, S., Cascio, A. S., Omodeo Salè, E., & Ceci, F.
Affiliations
  • European Institute of Oncology (IT)
  • Division of Nuclear Medicine, Humanitas IRCCS, 20141 Milan, Italy
  • Division of Nuclear Medicine, Hospital Clínico Universitario Lozano Blesa, 50009 Zaragoza, Spain
  • Division of Pharmacy, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy
  • University of Milan (IT)
Corresponding author
Mattana, Francesco
Venue
Cancers
Publisher
MDPI AG
Published
2024-04-25
Volume
16
Issue
9
Pages
1643
ISSN
2072-6694 (ISSN-L)
OpenAlex
W4395453742
Cited by
16
References
61
Citations by year
2026: 2 · 2025: 8 · 2024: 6
FWCI
1.03
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
Keywords
prostate-specific membrane antigen, PSMA-targeted therapy, prostate cancer, metastatic castration-resistant prostate cancer, 177Lu-PSMA-617, radiopharmaceuticals, PET/CT imaging, VISION trial, combination therapy, primary resistance, tumor heterogeneity, history of nuclear medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prostate-Specific Membrane Antigen-Targeted Therapy in Prostate Cancer: History, Combination Therapies, Trials, and Future Perspective. https://app.cochat.ai/papers/10.3390/cancers16091643
The paper
Mattana, F., Muraglia, L., Barone, A., Colandrea, M., Saker Diffalah, Y., Provera, S., Cascio, A. S., Omodeo Salè, E., & Ceci, F. (2024). Prostate-Specific Membrane Antigen-Targeted Therapy in Prostate Cancer: History, Combination Therapies, Trials, and Future Perspective. Cancers. https://doi.org/10.3390/cancers16091643

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.